Show simple item record

dc.contributor.authorWeber, J
dc.contributor.authorD'Angelo, S
dc.contributor.authorMinor, D
dc.contributor.authorHodi, F
dc.contributor.authorGutzmer, R
dc.contributor.authorNeyns, B
dc.contributor.authorHoeller, C
dc.contributor.authorKhushalani, N
dc.contributor.authorMiller, W
dc.contributor.authorLao, C
dc.contributor.authorLinette, G
dc.contributor.authorThomas, L
dc.contributor.authorLorigan, Paul C
dc.contributor.authorGrossmann, K
dc.contributor.authorHassel, J
dc.contributor.authorMaio, M
dc.contributor.authorSznol, M
dc.contributor.authorAscierto, P
dc.contributor.authorMohr, P
dc.contributor.authorChmielowski, B
dc.contributor.authorBryce, A
dc.contributor.authorSvane, I
dc.contributor.authorGrob, J
dc.contributor.authorKrackhardt, A
dc.contributor.authorHorak, C
dc.contributor.authorLambert, A
dc.contributor.authorYang, A
dc.contributor.authorLarkin, J
dc.date.accessioned2015-04-16T15:13:57Zen
dc.date.available2015-04-16T15:13:57Zen
dc.date.issued2015-04en
dc.identifier.citationNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. 2015, 16 (4):375-84 Lancet Oncolen
dc.identifier.issn1474-5488en
dc.identifier.pmid25795410en
dc.identifier.doi10.1016/S1470-2045(15)70076-8en
dc.identifier.urihttp://hdl.handle.net/10541/550190en
dc.description.abstractNivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with advanced melanoma.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentMoffitt Cancer Center, Tampa, FL, USA.en
dc.identifier.journalLancet Oncologyen
html.description.abstractNivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with advanced melanoma.


Files in this item

This item appears in the following Collection(s)

Show simple item record